Hot Features
Premium
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Period:
Draw Mode:
| Volume | 85,468 |
|
|||||
| News | - | ||||||
| Day High | 0.0065 | Low High |
|||||
| Day Low | 0.005 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| NovAccess Global Inc (QB) | XSNX | OTCMarkets | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.0065 | 13:32:55 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.006485 | 0.005 | 0.0065 | 0.0065 | 0.0065 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 5 | 85,468 | US$ 0.005357 | US$ 458 | - | 0.005 - 0.22 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 13:32:55 | 15,400 | US$ 0.0065 | USD |
NovAccess Global Inc (QB) Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 276.74k | 21.44M | 4.76M | 0 | -4.77M | -0.17 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
NovAccess Global (QB) News
| Date | Time | Source | News Article |
|---|---|---|---|
| 2/28/2024 | 14:06 | Edgar (US Regulatory) | Form 8-K - Current report |
| 2/27/2024 | 15:52 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 2/15/2024 | 07:38 | Edgar (US Regulatory) | Form NT 10-Q - Notification of inability to timely file Form.. |
| 2/09/2024 | 11:40 | Edgar (US Regulatory) | Form 10-K - Annual report [Section 13 and 15(d), not S-K.. |
| 2/06/2024 | 07:47 | Edgar (US Regulatory) | Form 8-K - Current report |
| 1/22/2024 | 12:44 | Edgar (US Regulatory) | Form 8-K - Current report |
| 1/18/2024 | 15:02 | Edgar (US Regulatory) | Form SC 13G - Statement of acquisition of beneficial.. |
| 1/05/2024 | 07:49 | Edgar (US Regulatory) | Form 8-K - Current report |
| 1/02/2024 | 14:55 | Edgar (US Regulatory) | Form 8-K - Current report |
| 1/02/2024 | 11:31 | Edgar (US Regulatory) | Form NT 10-K - Notification of inability to timely file Form.. |
| 12/21/2023 | 13:30 | Edgar (US Regulatory) | Form 8-K - Current report |
| 9/11/2023 | 08:27 | Edgar (US Regulatory) | Form 8-K - Current report |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical XSNX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.005 | 0.0074 | 0.005 | 0.0055535 | 1,299,450 | 0.0015 | 30.00% |
| 1 Month | 0.0125 | 0.0141 | 0.005 | 0.0074327 | 957,263 | -0.006 | -48.00% |
| 3 Months | 0.0246 | 0.033 | 0.005 | 0.0099391 | 647,155 | -0.0181 | -73.58% |
| 6 Months | 0.04 | 0.054 | 0.005 | 0.0150629 | 420,751 | -0.0335 | -83.75% |
| 1 Year | 0.1375 | 0.22 | 0.005 | 0.0173136 | 237,343 | -0.131 | -95.27% |
| 3 Years | 0.4651 | 0.97 | 0.005 | 0.0405256 | 84,966 | -0.4586 | -98.60% |
| 5 Years | 0.0005 | 0.97 | 0.0002 | 0.0023704 | 1,328,821 | 0.006 | 1,200.00% |
NovAccess Global (QB) Description
| NovAccess Global Inc. is a biopharmaceutical company focused on the development and commercialization of novel immunotherapies to treat brain tumor patients in the United States with plans to expand globally. We are experts in cutting-edge research involving the use of a patient's own immune system to fight cancer. Through our advisory board we have experience successfully executing clinical trials, bringing products to market and increasing the market size of products. Our scientists are well versed in immunology, stem cell biology, neuroscience, molecular biology, imaging, small molecule development and gene therapy as well as other technical assays required for protein and genetic analysis of cancer cells. NovAccess Global is a research and development (R&D) company based in Ohio and California, and our executive management and scientific advisory board have over 15 years of experience in all aspects of biopharmaceutical R&D and commercialization of drug candidates. |
